1d
Hosted on MSNTreating Generalized Myasthenia GravisRecently approved treatments for generalized myasthenia gravis (gMG), including complement and neonatal Fc receptor (FcRn) ...
Adding the anti-CD20 monoclonal antibody obinutuzumab (Gazyva) to standard therapy for lupus nephritis is more efficacious ...
3d
Medpage Today on MSNSemaglutide Tied to Small Risk of Potentially Blinding Eye ConditionThe use of semaglutide (Ozempic) was tied to a small risk of nonarteritic anterior ischemic optic neuropathy (NAION) in ...
The campaign is based on the results of a survey that reveals the experiences of patients and caregivers in their communities ...
Genentech and Novartis have teamed up with Food Allergy Research & Education (FARE) to enhance the safety of children with ...
Roche’s U.S. biotech subsidiary Genentech has wiped its website of past diversity reports as the company’s diversity and ...
To learn more about food allergies or access FARE resources, please visit foodallergy.org.
Genentech has shared positive data from the Phase III REGENCY trial with regulators in the US and EU. Roche’s subsidiary ...
Kineta has found a new home for deals with Genentech and Merck & Co. Tidying up the portfolio ahead of its merger with TuHURA ...
If this CEO succeeds N-Power could save millions of dollars and lives in the fight against cancer. "The impact for cancer ...
FDA Approves Genentech’s Evrysdi Tablet as First and Only Tablet for Spinal Muscular Atrophy (SMA)
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results